Quick Answer
CNBX Pharmaceuticals Inc. reported Research And Development Expense of $0.00 for the year ending 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -100.0% in Research And Development Expense from 2024 to 2025.
- This data is from CNBX Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on December 1, 2025.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $194.8 thousand | Fiscal year 2023: $431.6 thousand | Fiscal year 2022: $1.18 million | Fiscal year 2021: $1.77 million | Fiscal year 2020: $1.68 million | Fiscal year 2019: $1.54 million | Fiscal year 2018: $1.00 million | Fiscal year 2017: $246.9 thousand | Fiscal year 2016: $177.6 thousand | Fiscal year 2015: $139.4 thousand | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: